Transgender and gender-diverse (TGD) breast cancer patients are more likely to be diagnosed with ductal carcinoma in situ (DCIS) and be younger compared with their cisgender counterparts, according to research published May 22 in JAMA Oncology.
A team led by Chandler Cortina, MD, from Medical College of Wisconsin in Milwaukee also found that transgender women are less likely to receive endocrine therapy for hormone receptor (HR)-positive breast cancers and postmastectomy breast reconstruction.
“This information tells us that there are clear breast cancer treatment and outcome disparities in the [transgender] population and that there is much opportunity to improve outcomes through evidence-based gender-specific screening and treatment guidelines,” Cortina told AuntMinnie.
Data are sparse when it comes to…